1-4 of 4
Erika P. Hamilton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Matthew P. Goetz, Erika P. Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2233–2244.
https://doi.org/10.1158/1078-0432.CCR-22-3573
Published: 15 May 2024
View articletitled, Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Open the PDF for Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Kathleen N. Moore, Setsuko K. Chambers, Erika P. Hamilton, Lee-may Chen, Amit M. Oza, Sharad A. Ghamande, Gottfried E. Konecny, Steven C. Plaxe, Daniel L. Spitz, Jill J.J. Geenen, Tiffany A. Troso-Sandoval, Janiel M. Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M. Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel, Karen A. Cadoo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 36–44.
https://doi.org/10.1158/1078-0432.CCR-21-0158
Published: 05 January 2022
View articletitled, Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
Open the PDF for Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study in another window
Includes: Supplementary data
Journal Articles

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Devalingam Mahalingam, Judy S. Wang, Erika P. Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall Schreeder, H. Jeffrey Wilkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (12): 3508–3516.
https://doi.org/10.1158/1078-0432.CCR-18-3185
Published: 14 June 2019
View articletitled, Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Open the PDF for Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

Erika P. Hamilton, Manish R. Patel, Anne C. Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah R. Morgan, Gaia Schiavon, Hazel M. Weir, Seock-Ah Im
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3510–3518.
https://doi.org/10.1158/1078-0432.CCR-17-3102
Published: 31 July 2018
View articletitled, A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Open the PDF for A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer in another window
Includes: Supplementary data